An inducible caspase 9 safety switch for T-cell therapy.

By K. Straathof, M. Pule, P. Yotnda, G. Dotti, E. Vanin, M. Brenner, H. Heslop, D. Spencer, C. Rooney. Blood, 2005

740 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d16f7c77f73f4dbfd5124387c093170e5dc8c426

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. C. D. Allis
2. T. Mak
3. T. Berger
4. David Mcilwain

In Molecular Biology

1. Shahin Rafii
2. C. D. Allis
3. M. Holmes
4. Jeffrey C. Miller
5. F. Urnov
6. T. Mak
7. T. Berger
8. David Mcilwain

In Oncology

1. T. Mak

Citations in the corpus

• Distinct factors control histone variant H3.3 localization at specific genomic regions (2010, methodology): “For TFBS profiling, binding sites for 13 TFs in mouse ESCs were obtained from a previous ChIP-seq analysis (Chen et al., Cell 140, 678–691, March 5, 2010 ª2010 Elsevier Inc. 687 Hira GFP Oct4 Atrx Atrx flox Atrx null 1 Atrx null 2 Hira -/- H3.”
• Caspase functions in cell death and disease. (2013, background): “The majority of ALPS patients have dominant mutations in CD95, CD95L, or CASP10 (Lenardo et al. 1999; Straus et al. 1999; Wang et al. 1999).”